The development of a novel PARP inhibitor with potent antitumor activity in various tumor xenograft models

被引：0
|
作者：
Park, Ji-Seon [1 ]
Kim, Jang-Hyun [1 ]
Cheon, Kwang-Woo [1 ]
Cho, Bo-Young [1 ]
Kim, Kang-Jeon [1 ]
Lee, Han-Chang [1 ]
Kim, Young-Cheol [1 ]
Oh, Hyung-Chan [1 ]
Lee, Hyun-Ho [1 ]
Kim, Jeong-Min [1 ]
机构：
[1] JEIL Pharm, Yongin, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
825
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
    Hung Huynh
    Richard Ong
    Dieter Zopf
    Journal of Experimental & Clinical Cancer Research, 34
  • [42] Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
    Yap, Timothy A.
    Walton, Mike I.
    Hunter, Lisa-Jane K.
    Valenti, Melanie
    Brandon, Alexis de Haven
    Eve, Paul D.
    Ruddle, Ruth
    Heaton, Simon P.
    Henley, Alan
    Pickard, Lisa
    Vijayaraghavan, Gowri
    Caldwell, John J.
    Thompson, Neil T.
    Aherne, Wynne
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Workman, Paul
    Collins, Ian
    Garrett, Michelle D.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (02) : 360 - 371
  • [43] The PARP inhibitor, rucaparib enhances the antitumor activity of 177Lu-DOTA-octreotate radionuclide therapy in preclinical models of neuroendocrine tumor
    Cullinane, Carleen
    Waldeck, Kelly
    Eu, Peter
    Hicks, Rodney J.
    CANCER RESEARCH, 2015, 75
  • [44] The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model
    Xu, Yunze
    Zhu, Qi
    Chen, Dongning
    Shen, Zhoujun
    Wang, Weiqing
    Ning, Guang
    Zhu, Yu
    TUMOR BIOLOGY, 2015, 36 (07) : 5103 - 5108
  • [45] Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma
    Wang, Yannick
    Wozniak, Agnieszka
    Cornillie, Jasmien
    Aviles, Pablo
    Debiec-Rychter, Maria
    Sciot, Raf
    Schoffski, Patrick
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [46] Novel hemisynthetic derivatives of Amaryllidaceae alkaloids exert antitumor activity on xenograft melanoma models
    Annereau, Jean-Philippe
    Marion, Frederic
    Fournier, Emmanuel
    Vandenberghe, Isabelle
    Vispe, Stephane
    Pouny, Isabelle
    Sautel, Francois
    Aussagues, Yannick
    Ausseil, Frederic
    Gomes, Bruno
    Fahy, Jacques
    Bailly, Christian
    Kruczynski, Anna
    Guilbaud, Nicolas
    CANCER RESEARCH, 2011, 71
  • [47] Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
    Daenen, Laura G.
    Shaked, Yuval
    Man, Shan
    Xu, Ping
    Voest, Emile E.
    Hoffman, Robert M.
    Chaplin, David J.
    Kerbel, Robert S.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (10) : 2872 - 2881
  • [48] A preclinical evaluation of niraparib efficacy as monotherapy, maintenance and after olaparib treatment (PARP inhibitor after PARP inhibitor) in patient-derived ovarian xenograft tumor models
    Mikule, K.
    Wang, S.
    Weroha, S. J.
    Nakashima, J.
    Wilcoxen, K.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S96 - S96
  • [49] Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell
    Wang, Zheng
    Li, Pei
    Xu, Qinhong
    Xu, Jun
    Li, Xuqi
    Zhang, Xufeng
    Ma, Qingyong
    Wu, Zheng
    PLOS ONE, 2013, 8 (06):
  • [50] Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models
    Chau, Y
    Padera, RF
    Dang, NM
    Langer, R
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (06) : 1519 - 1526
12345